RecruitingNot applicableNCT07188532
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Studying Skeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Roman O. Kowalchuk, MD, MDMayo Clinic in Rochester
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 141 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07188532 on ClinicalTrials.govOther trials for Skeletal Ewing sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06699472A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibFudan University
- RECRUITINGPHASE1, PHASE2NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05968768To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)Anna Raciborska
- RECRUITINGPHASE1NCT06156410Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasChildren's Hospital of Philadelphia